Visit our USA website
In a year where the number of Americans living with Alzheimer’s disease has surpassed 7 million for the first time, a new report from the Alzheimer’s Association reveals a clear message from the public: early detection and access to treatment matter deeply, even if there are risks involved. This growing urgency has been observed by Re:Cognition Health doctors over the last several years, reflecting both the scale of the disease and Americans’ increasing awareness of the benefits of early intervention.
According to the 2025 Alzheimer’s Disease Facts and Figures report and its accompanying special survey, nearly 80% of Americans aged 45 and older want to know if they have Alzheimer’s before symptoms interfere with their lives. Most would also prefer to undergo a simple diagnostic test, such as a blood test, to catch the disease early. This strong preference is fuelled by the belief that early diagnosis can lead to better access to treatments and care, and potentially improve quality of life.
In fact, 91% said they would take a simple test if it were available, and 80% would actively ask to be tested rather than wait for a doctor’s suggestion. The appetite for answers reflects growing awareness of new treatments that can slow the disease progression of Alzheimer’s, such as Leqembi and Kisunla, even if not yet curative.
Nearly 80% of Americans aged 45 and older want to know if they have Alzheimer’s before symptoms interfere with their lives
2025 Alzheimer’s Disease Facts and Figures Report
This readiness to act comes with a remarkable willingness to take medical risks. Nearly 60% of Americans surveyed would accept moderate to high risks with medication that could slow the disease in its early stages. Nearly one in four said they would accept high risk- a powerful indication of the emotional and practical toll Alzheimer’s imposes on individuals and families.
The report also notes a strong desire to contribute to the fight against the disease: 83% of respondents would consider joining a clinical trial if diagnosed. Optimism about the future is also evident, with 81% believing that new treatments to halt Alzheimer’s progression will be available in the next decade, and two-thirds hopeful about preventive therapies.
Dr. Emer MacSweeney, CEO and Medical Director at Re:Cognition Health comments, “The willingness of so many Americans to participate in clinical trials reflects a powerful commitment to progress. At Re:Cognition Health, we’ve seen how research not only offers hope to individuals diagnosed with Alzheimer’s but also accelerates access to potentially life-changing treatments. Early diagnosis opens the door to these opportunities — and to the chance of changing the future for millions.”
However, early testing also raises concerns. Many worry about insurance coverage, test accuracy, costs and the emotional impact of a diagnosis, especially before symptoms emerge. 44% fear that health insurance might not cover future care, and 41% are concerned about test reliability.
The report also underscores the immense financial burden of Alzheimer’s:
- 7.2 million Americans aged 65+ are currently living with the disease
- Care costs are projected to reach $384 billion in 2025, not including nearly $413 billion in unpaid care provided by friends and family
In response to these findings, the Alzheimer’s Association is pushing forward several key efforts:
- Improving access to blood-based biomarker testing, with new clinical guidelines expected in 2025
- Training physicians to better communicate testing and treatment options
- Advocating for insurance coverage and public education to close care gaps
- Balancing early detection with ethical care, ensuring patients receive the support needed to interpret results
“Advances in diagnostic tools, particularly blood biomarker testing, are revolutionising how we detect Alzheimer’s disease, and this report confirms the public is ready to embrace them. Early and accurate diagnosis is the foundation of effective treatment, and at Re:Cognition Health, we are proud to be at the forefront of bringing these innovations into clinical practice.”
Dr. Scott Turner, Neurologist and Principal Investigator at Re:Cognition Health USA
As Alzheimer’s becomes an even more pressing national health challenge, this year’s report is a rallying call to clinicians, researchers, policymakers and families. Americans want answers. They want hope. And most of all, they want the chance to take action, even before symptoms begin.
For more information and the full report, visit https://www.alz.org/news/2025/facts-figures-report-alzheimers-treatment
To enquire about our new generation Alzheimers medications and clinical trials, please contact us.
